Anticoagulant therapy is usually used after endovascular operations like coil embolization of aneurysms, or for thromboembolic diseases such as myocardial infarction. Few data exist regarding hemorrhage from benign brain tumors during systemic heparinization with the exception of pituitary adenomas 1,2. We experienced two cases of hemorrhage from benign brain tumors during systemic heparinization. The first patient had an unruptured aneurysm in her suprasellar tumor. She underwent coil embolization to prevent hemorrhage during the subsequent tumorectomy. During and after the endovascular operation, she was heparinized and she suffered a hemorrhage from the tumor on the first postoperative day. The second patient had a suprasellar tumor and was heparinized prophylactically for myocardial infarction. He had an intratumoral hemorrhage on the fifth day after the start of the heparinization. This small series suggests that systemic heparinization with brain tumors, even when they are benign, is very dangerous, and further studies with a larger patient base are warranted. 26(4): 260-263, 1992. 12 Suzuki S, Matsuo T et AI: Antithrombotic treatment (Argatroban vs. heparin) in coronary angioplasty in angina pectoris: effects on inflammatory, hemostasic, and endothelium-derived parameters. Thromb Res 98: 269-279,2000. 13 Ohteki H, Furukawa K et AI: Clinical experience of argatroban for anticoagulation in cardiovascular surgery.
Introduction
In 1972,00 et Al reported his first case of pituitary apoplexy on the third day after heparin anticoagulation for acute myocardial infarction 2.
No other reports have appeared on hemorrhage from benign brain tumors during systemic anticoagulant therapy, with the exception of pituitary adenomas.
In this study, we report two cases of hemorrh age from benign suprasellar tumors during systemic heparin anticoagulation therapy. These two cases suggest that systemic heparinization presents a high risk when the patient has a brain tumor, even if it is benign.
Case histories

Case 1
A 60-year-old woman had been suffering from left abducens palsy since 1993. Suprasellar tumor was diagnosed at another hospital. Conservative therapy with steroids was started, and she was followed up. For the next five years the severity of her symptoms varied widely. In June 1999, her symptoms significantly worsened, a neuroradiological examination revealed her tumor had grown and she was admitted for surgery. A neurological examination on admittance demonstrated left oculomotor, trochlear and abducens nerve palsy. Her physical examination and blood chemistry were within normal limits. Angiography showed a left internal carotid aneurysm, which MRI revealed to be surrounded by a suprasellar tumor (figure 1). The preoperative diagnosis was a chordoma. A tumorectomy was planned and coil embolization was performed to prevent intraoperative rupture of the aneurysm. From the start of embolization, systemic heparinization was performed to avoid infarction. Serum ACT was maintained at twice the control level. At noon on the following day, she suddenly lost consciousness, and CT revealed a slightly increased T. Nakagawa density in her tumor (figure 2), suspected as an intratumoral hemorrhage. Systemic heparinization was stopped and reversed soon after CT revealed a subarachnoid hemorrhage at 19.00 on the same day (figure 3). Angiography was performed which showed the aneurysm had been completely packed (figure 4) . Ventricular drainage was performed for acute hydrocephalus but she died from severe pneumonia in November, 1999.
Case 2
An 83-year-old man suffered gait disturbance and a suprasellar tumor was diagnosed in 1997 (figure 5). He was followed up conservatively because of his age. He was admitted to the cardiology department for acute angina in June, 1999. The neurological examination was normal, as were the physical examination and the blood chemistry. Systemic heparinization was performed by the cardiology team and APTT was maintained at twice the control level. Systemic heparinization was continued for four days. On the fifth day following the start of this therapy, the patient suddenly lost consciousness, and a CT scan showed intratumoral and intraventricular hemorrhage (figure 6) . His symptoms improved and he was discharged in July.
In September, he suffered a pulmonary embolism and systemic anticoagulant therapy was restarted at another hospital, following which he once again suffered from an intratumoral hemorrhage. He was transferred to our hospital, but he died in December 1999.
Discussion
In Case 1 the hemorrhage in the subarachnois space was seen only in the tumor at noon on the day following the coil embolization. Angiography showed that the aneurysm had been completely packed by the coil, indicating that this hemorrhage had occured in the turn or. In both our cases, the exact tumor pathology was unknown because an autopsy was not performed in either case, but neuroradiological examination suggested benign tumors. Case 1 was diagnosed as a chordoma, case 2 as a craniopharyngioma.
Wakai et Al examined 1,861 cases involving brain tumors over 18 years (1964) (1965) (1966) (1967) (1968) (1969) (1970) (1971) (1972) (1973) (1974) (1975) (1976) (1977) (1978) (1979) (1980) (1981) (1982) , and he found six cases of intratumoral hemorrhage in chordoma and 91 cases in craniopharyngioma 3 . Kondziolka et Al examined 905 cases involving brain tumors over 16 years (1970) (1971) (1972) (1973) (1974) (1975) (1976) (1977) (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) (1986) ), but he did not find any cases of intratumoral hemorrhage in either chordomas or craniopharyngiomas 4. Their data suggest that spontaneous hemorrhage from chordomas and craniopharyngiomas is not frequent, but in both our cases, intratumoral hemorrhage occurred soon after systemic heparinization, which we think was responsible for these intratumoral hemorrhages. It is understandable that hemorrhage from a malignant brain tumor is likely to occur because of its hypervascularity and there are many reports of hemorrhage from metastatic brain tumors under systemic heparinization 5,6.7,8.9 , but there is no report of hem-orrhage from chordomas or craniopharyngiomas during systemic heparinization.
The serum criteria of ACT and APTT levels for heparin anticoagulant therapy is usually about twice the control level 10,11 which was the case in our patients. In Case 1, heparin was used for one day, in Case 2 for four days, so neither the dose nor the duration of heparin was above the norm.
We suggest that heparin anticoagulant therapy in patients with a brain tumor is a high risk therapy even if the tumor has a very low hem orrhagic probability. In our Case 1, the aneurysm was surrounded by tumor tissue, so coil embolization was performed to avoid rupture of the aneurysm during tumorectomy. The outcome in this case suggests that we should limit the time and dose of heparin when benign brain tumor and aneurysm co-exist and consider another treatment method, for example IC trapping.
If the tumor is located away from the aneurysm, systemic heparinization can cause intratumoral hemorrhage. In such case, we should carry out the tumorectomy as the first stage of surgery, and then perform a coil embolization as the second stage. On the other hand, in those cases where systemic anticoagu- T. Nakagawa lant therapy is necessary as an emergency procedure such as in Case 2, we should check the patient's neurological status carefully after starting heparin anticoagulant therapy, and be prepared to perform a CT scan as soon as possible after any deterioration in the patient's condition. We believe that it is necessary to check for the existence of brain tumors before initiating anticoagulant therapy. Many reports have suggested that argatrobane is useful as a substitute for heparin in the cardiovascular field 12.13 , and no report has appeared on hemorrhage from brain tumors during argatrobane therapy, suggesting it is an appropriate alternative to heparin.
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